Verastem Oncology reports promising initial results from the RAMP 205 trial with an 83% ORR for avutometinib and defactinib in metastatic pancreatic cancer. FDA submission for recurrent KRAS mutant ovarian cancer is underway.
including the pricing of a $40 million underwritten public offering of 38,095,238 of the Company's Class A ordinary shares (the "Shares") and warrants to purchase 38,095,238 Shares (the "Warrants" and, together with the
Visionary Holdings Inc. ("we", or the "Company") (NASDAQ:GV), a private education provider with technology of artificial intelligence and life science on the cutting edge, with subsidiaries in Canada and market partners
Buckle reported a 7.2% YoY decline in Q1 FY24 sales to $262.48M, missing the $263.64M analyst estimate. Comparable store net sales fell 9%, while online sales dropped 13.4%.